This week in drug discovery (4-8 March) 

News round-up for 4-8 March by DDW Digital Content Editor Diana Spencer.

It was antibodies hitting the headlines this week, with the discovery of antibodies with potential against a new influenza target, the launch of a Phase I trial to investigate a novel type of bispecific antibody, and the announcement that the FDA will delay approval of donanemab to hold a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee.

The top stories:

Antibody therapy shows anti-tumour activity in advanced cancer

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer.

Novel antibodies target ‘dark side’ of influenza virus protein

Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored ‘dark side’ of the neuraminidase (NA) protein head.

Humanised bispecific antibody for asthma enters Phase I trial

Biopharmaceutical company Innovent Biologics has launched the first-in-human (FIH) Phase I clinical trial of IBI3002, a novel bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP).

New R&D collaboration to advance Alport Syndrome programme

Fibrocor Therapeutics has entered into a research and development (R&D) collaboration with the McQuade Center for Strategic Research and Development (MSRD) to advance its Alport Syndrome programme.

FDA advisory committee meeting delays approval of donanemab

The US Food and Drug Administration (FDA) has revealed plans to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase III TRAILBLAZER-ALZ 2 trial.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free